Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Johannsen

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
BMC Cancer|June 28, 2008
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progressionFlorian R Fritzsche, Kirsten Wassermann, Monika Jung, et al.
Actas Urologicas Espanolas|September 28, 2007
[Thermal therapy of prostate cancer using magnetic nanoparticles]Manfred Johannsen, Uwe Gneveckow, Kasra Taymoorian, et al.
European Urology|October 28, 2008
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysisManfred Johannsen, Anne Flörcken, Axel Bex, et al.
European Urology|May 3, 2008
Identification of stanniocalcin 2 as prognostic marker in renal cell carcinomaHellmuth-A Meyer, Angelika Tölle, Monika Jung, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 30, 2009
Expression of Mcl-1 splicing variants in clear-cell renal cancer and their correlation with histopathological parameters and prognosisCarsten Kempkensteffen, Stefan Hinz, Manfred Johannsen, et al.
Journal of Cellular and Molecular Medicine|October 23, 2009
Metabolic profiling reveals key metabolic features of renal cell carcinomaGareth Catchpole, Alexander Platzer, Cornelia Weikert, et al.
European Urology|November 28, 2006
Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distributionManfred Johannsen, Uwe Gneveckow, Burghard Thiesen, et al.
World Journal of Urology|April 23, 2011
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitorsSteffen Weikert, Carsten Kempkensteffen, Jonas Busch, et al.
Cancer Immunology, Immunotherapy : CII|October 31, 2009
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant settingMatthias May, Sabine Brookman-May, Bernd Hoschke, et al.
The Prostate|February 24, 2005
Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat modelManfred Johannsen, Burghard Thiesen, Andreas Jordan, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
BMC Cancer|June 28, 2008
ADAM9 is highly expressed in renal cell cancer and is associated with tumour progressionFlorian R Fritzsche, Kirsten Wassermann, Monika Jung, et al.
Actas Urologicas Espanolas|September 28, 2007
[Thermal therapy of prostate cancer using magnetic nanoparticles]Manfred Johannsen, Uwe Gneveckow, Kasra Taymoorian, et al.
European Urology|October 28, 2008
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysisManfred Johannsen, Anne Flörcken, Axel Bex, et al.
European Urology|May 3, 2008
Identification of stanniocalcin 2 as prognostic marker in renal cell carcinomaHellmuth-A Meyer, Angelika Tölle, Monika Jung, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 30, 2009
Expression of Mcl-1 splicing variants in clear-cell renal cancer and their correlation with histopathological parameters and prognosisCarsten Kempkensteffen, Stefan Hinz, Manfred Johannsen, et al.
Journal of Cellular and Molecular Medicine|October 23, 2009
Metabolic profiling reveals key metabolic features of renal cell carcinomaGareth Catchpole, Alexander Platzer, Cornelia Weikert, et al.
European Urology|November 28, 2006
Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distributionManfred Johannsen, Uwe Gneveckow, Burghard Thiesen, et al.
World Journal of Urology|April 23, 2011
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitorsSteffen Weikert, Carsten Kempkensteffen, Jonas Busch, et al.
Cancer Immunology, Immunotherapy : CII|October 31, 2009
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant settingMatthias May, Sabine Brookman-May, Bernd Hoschke, et al.
The Prostate|February 24, 2005
Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat modelManfred Johannsen, Burghard Thiesen, Andreas Jordan, et al.
Pageof 6